BioPharmSignal logoBioPharmSignal

Biotech News

GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars

GRI Bio (GRI)GRI BioCompany update

New whole blood RNA sequencing data identified coordinated, consistent change in genes governing immune re-balancing, myofibroblast inhibition, fibrolysis, basement membrane repair, re-epithelialization, antitussive effect and GI protection

Signals observed from at least two independent measurement modalities,...

Related news

GRIGRI Bio2026-08-24 14:05 EST

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

GRIGRI Bio2026-09-28 13:40 EST

GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit

ARGXArgenx2026-09-29 12:00 EST

argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline

BMYBMYBristol-Myers Squibb Company2026-08-29 15:00 EST

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

MLTXMoonLake Immunotherapeutics2026-08-10 11:00 EST

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

View all latest news

GRI Bio

BioRestorative or GRI is a historical small-cap biotech entry tied to biologics and regenerative or related platform work. Its story is best understood as an early-stage development attempt rather than a mature commercial franchise.

Recent company news

GRIGRI Bio2026-09-28 13:40 EST

GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit

GRIGRI Bio2026-09-08 13:15 EST

GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars

GRIGRI Bio2026-09-08 13:15 EST

GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars

GRIGRI Bio2026-08-27 14:01 EST

GRI Bio Featured in "Why Now" On-Demand Video Webcast

GRIGRI Bio2026-08-24 14:05 EST

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

Stock data

Close
1.96 USD
Market cap
3.56M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States